Medicine and Dentistry
Ovarian Cancer
100%
Endometrial Cancer
66%
Krukenberg Tumor
65%
Neoplasm
49%
Hysterectomy
37%
Gynecological Oncology
33%
Tumor Progression
31%
Malignant Neoplasm
25%
Overall Survival
22%
Sentinel Lymph Node
21%
Surgery
20%
Small Interfering RNA
20%
Endometrium Carcinoma
19%
Recurrent Disease
19%
Minimally Invasive Surgery
18%
Tumor Cell
17%
Odds Ratio
17%
Platelet
17%
Progression Free Survival
16%
Surgeon
16%
Disease
15%
Cytoreductive Surgery
15%
Cancer Cell
14%
Salpingectomy
14%
Retroperitoneal Lymph Node Dissection
13%
Enhanced Recovery After Surgery
13%
Atypical Hyperplasia
12%
Lymph Node
12%
Health Care Cost
12%
Angiogenesis
12%
Adjuvant Therapy
11%
Bevacizumab
11%
Indocyanine Green
11%
Body Mass Index
10%
Cancer Growth
10%
Metastatic Carcinoma
10%
Cervical Cancer
10%
Venous Thromboembolism
10%
Clear Cell Carcinoma
10%
Hazard Ratio
10%
Pelvis
10%
Lymph Duct
10%
Oncologist
9%
Programmed Cell Death
9%
Vasculotropin
9%
Antiangiogenic Therapy
9%
Ectopic Pregnancy
8%
Squamous Cell Carcinoma
8%
Glycon
8%
Focal Adhesion Kinase
8%
Keyphrases
Ovarian Cancer
51%
Endometrial Cancer
35%
Tumor Growth
22%
Ovarian Carcinoma
22%
Small Interfering RNA (siRNA)
19%
Chemotherapy
18%
Clinical Cancer Research
17%
Tumor
17%
CD31
17%
Platelets
17%
Endometrioid Endometrial Cancer
16%
Hysterectomy
15%
Gynecologic Oncology
15%
Confidence Interval
14%
Overall Survival
13%
Epithelial Ovarian Cancer
13%
Focal Adhesion Kinase
13%
Sentinel Lymph Node Mapping
13%
Tumor Cells
12%
Bevacizumab
12%
Apologizing
11%
Progression-free Survival
11%
Serous Ovarian Carcinoma
11%
Stress Effect
10%
Adjuvant Therapy
10%
Cancer Growth
10%
Venous Thromboembolism
9%
Gene Silencing
9%
Chitosan Nanoparticles
9%
Lymphovascular Invasion
9%
Resource Needs
8%
Interleukin-8
8%
Ovarian Clear Cell Carcinoma
8%
Notch Ligands
8%
EphB4
8%
Cancer Metastasis
8%
Early Endometrial Cancer
8%
Antiangiogenic Therapy
8%
Pembrolizumab
8%
July Effect
8%
Social Resources
8%
Metformin
8%
Indocyanine Green
8%
Targeted Gene
8%
EphA2
8%
FosB
8%
Atypical Hyperplasia
8%
Ovarian Cancer Cells
8%
Dasatinib
8%
Minimally Invasive Hysterectomy
7%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
78%
Neoplasm
62%
Ovary Carcinoma
46%
Tumor Growth
40%
Small Interfering RNA
37%
Malignant Neoplasm
27%
Cancer Growth
18%
Vasculotropin
17%
Mouse
15%
Bevacizumab
15%
Metastasis
14%
Antiangiogenic Therapy
13%
Chemotherapy
13%
Endometrium Carcinoma
11%
Paclitaxel
10%
Focal Adhesion Kinase
9%
Chitosan Nanoparticle
9%
Interleukin 8
8%
Retrospective Study
8%
Pembrolizumab
8%
Clear Cell Carcinoma
8%
Adverse Outcome
8%
Thrombocytosis
8%
Noradrenalin
8%
Docetaxel
8%
Taxane
8%
Endometrium Cancer
8%
Disease
8%
Antiangiogenic
7%
Antitumor Activity
6%
Adrenergic Receptor
6%
Mouse Model
6%
Recurrent Disease
6%
Nanoparticle
5%
Cohort Study
5%
Phosphotransferase
5%
Venous Thromboembolism
5%
Carboplatin
5%
Combination Therapy
5%
Tumor Microenvironment
5%
Toxicity
5%
Chitosan
5%
Female Genital Tract Cancer
5%
